Characteristics of patients with vasculitis according to the presence or absence of three-vessel plaque
| Parameters | Three-vessel plaque | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | |||||||||
| Present (n = 25) | Absent (n = 25) | p Value | Present (n = 25) | Absent (n = 25) | p Value | |||||
| ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CHD, coronary heart disease. | ||||||||||
| Values are mean (SD) unless otherwise mentioned. | ||||||||||
| *Log transformed for statistical analysis. | ||||||||||
| High-risk status, n (%) | 11 (44) | 4 (16) | 0.038 | 10 (48) | 18 (23) | 0.020 | ||||
| C reactive protein, mg/l* | 7.4 (11.7) | 4.3 (3.5) | 0.310 | 3.9 (3.3 | 2.0 (1.6 | 0.030 | ||||
| Disease characteristics | ||||||||||
| BVAS | ||||||||||
| At time of diagnosis | 20.3 (6.8) | 17.0 (8.1) | 0.169 | — | — | |||||
| At time of evaluation | 1.0 (1.6) | 1.0 (1.7) | 1.000 | — | — | |||||
| ANCA presence, n (%) | ||||||||||
| At time of diagnosis | 14 (56) | 12 (48) | 0.636 | — | — | |||||
| At time of evaluation | 16 (64) | 13 (52) | 0.462 | — | — | |||||
| Treatment characteristics | ||||||||||
| Current corticotherapy, n (%) | 22 (88) | 25 (100) | 0.074 | — | — | |||||
| Current corticoid dose, mg/day | 8.3 (9.1) | 8.0 (5.1) | 0.883 | — | — | |||||
| Corticotherapy duration, years | 6.5 (6.6) | 8.4 (6.1) | 0.291 | — | — | |||||
| Other immunosuppressive treatment, n(%) | ||||||||||
| Azathioprine | 9 (36) | 11 (44) | 0.558 | — | — | |||||
| Cyclophosphamide | 17 (68) | 16 (64) | 0.763 | — | — | |||||
| Hydroxychloroquine | 0 | 2 (8) | 0.091 | — | — | |||||
| Methotrexate | 4 (16) | 5 (20) | 0.711 | — | — | |||||
| Mycophenolate mofetil | 2 (8) | 2 (8) | 1.000 | — | — | |||||